COVID-19 vaccine safety
DOI:
https://doi.org/10.17843/rpmesp.2021.384.9308Keywords:
Vaccine, Coronavirus, SARS-CoV-2, Spike Glycoprotein, Immunogenicity, Efficacy, Adverse events, Clinical Trial, Phase III, PandemicsAbstract
The development and production of safe and effective vaccines against coronavirus disease 2019 (COVID-19) provides hope for controlling the current pandemic. Adverse events following immunization are unwanted responses or unintended events that must be carefully monitored, as all vaccines, including those developed against SARS-CoV-2, are required to meet safety criteria for administration in humans. Information was collected from the PubMed/Medline database during the months of August 2020 to November 2021. Most adverse events reported in clinical trials were mild or moderate; however, thrombotic events associated with some viral vector-based vaccines against COVID-19 were identified in follow-up studies, although completion of the various ongoing studies and post-marketing surveillance is required to determine all potential adverse events, as well as those of special interest.Downloads
Download data is not yet available.
Downloads
Published
2021-12-22
Issue
Section
Review
License
Copyright (c) 2021 Revista Peruana de Medicina Experimental y Salud Pública
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
1.
Chaparro Mérida NA, Samper DM, Franco Lacato AO. COVID-19 vaccine safety. Rev Peru Med Exp Salud Publica [Internet]. 2021 Dec. 22 [cited 2024 Nov. 2];38(4):634-42. Available from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/9308